Drugmakers encouraged doctors to prescribe these drugs for children before the FDA sanctioned their use for youngsters. This was particularly troubling, given that the drugs can cause diabetes and weight gain, side effects that prompted thousands of lawsuits claiming that drugmakers tried to hide evidence of these problems.
A study published last month in the Journal of the American Medical Association found the drugs caused children and adolescents to gain an average of 19 pounds in 11 weeks of treatment. The concern with weight gain seen with most antipsychotic drugs is whether it causes additional problems such as diabetes and cardiovascular disease. A top Food and Drug Administration official said Tuesday the agency is considering strengthening the labels of antipsychotic drugs to warn about weight gain and diabetes amid concerns the impact could be stronger in children compared to adults.
FDA drug reviewers said medical researchers have found a direct link between the use of so-called atypical antipsychotics (Seroquel, Zyprexa, Abilify, Risperdal) in younger children and weight gain, high cholesterol, and increased blood pressure.
According to a new report commissioned by the British government, there are an estimated 180,000 elderly people with dementia in the United Kingdom currently being treated with antipsychotic drugs such as Seroquel, Zyprexa, Risperdal and Abilify. The report found that these drugs could be responsible for as many as 1,800 deaths and 1,620 strokes each year among the elderly with dementia in the United Kingdom.
Ironically, the FDA is approving these drugs for use in children at the same time that the Justice Department has been fining drug companies for illegally marketing these drugs to children. The illegal marketing corrupted and contaminated medical practice, encouraging physicians to prescribe off label, eventually leading the FDA to then approve off label prescribing. The studies used to justify this approval have been wholly developed and supervised by these same drugs companies using handpicked doctors who have often been involved in encouraging off label use. Drug companies commonly ghostwrite the research publications that appear under the names of these doctors.